Psoriasis Treatment Market Forecast 2031: Expected to Exceed US$44 Billion with 8.7% CAGR | TMR Insights

The global psoriasis treatment market, valued at US$18.8 billion in 2021, is poised for significant growth over the next decade. It is projected to advance at a robust compound annual growth rate (CAGR) of 8.7% from 2022 to 2031, surpassing US$44 billion by the end of 2031. This strong expansion reflects the rising prevalence of psoriasis, a chronic autoimmune skin condition, coupled with advancements in therapeutic options and increasing patient awareness. As healthcare systems prioritize dermatological care, the psoriasis treatment market is set to more than double in value, reinforcing its critical role in improving quality of life through 2031.

Get Sample PDF Brochure from here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17960

Understanding the Psoriasis Treatment Market

Psoriasis is a chronic inflammatory condition characterized by red, scaly skin patches, affecting millions globally and often accompanied by comorbidities like psoriatic arthritis. The market includes treatments such as topical therapies (e.g., corticosteroids), systemic drugs (e.g., methotrexate), and biologics (e.g., adalimumab, secukinumab), alongside phototherapy. The 2021 valuation of US$18.8 billion underscores its established importance, with the projected rise to over US$44 billion by 2031 highlighting its rapid response to growing clinical and patient needs.

The 8.7% CAGR signals a dynamic growth phase, fueled by innovation and demand. Psoriasis's impact on physical and mental well-being drives a robust treatment pipeline, ensuring sustained market momentum.

Key Drivers of Market Growth

Several factors are propelling the psoriasis treatment market toward its US$44 billion milestone by 2031. First, the increasing prevalence of psoriasis is a primary driver. Affecting approximately 2-3% of the global population-over 125 million people, per the National Psoriasis Foundation-rising incidence is linked to genetic factors, environmental triggers, and lifestyle changes. This growing patient pool aligns with the market's 8.7% CAGR, boosting demand for effective therapies.

Second, advancements in biologics and targeted therapies are accelerating growth. Biologics targeting specific pathways-like IL-17, IL-23, and TNF-alpha-offer superior efficacy and safety compared to traditional systemics, transforming psoriasis management. Drugs like ixekizumab and risankizumab, alongside biosimilars, expand treatment options, driving the market toward US$44 billion as patient outcomes improve.

Third, rising awareness and healthcare investments are boosting the market. Patient advocacy groups and dermatology campaigns are reducing stigma and encouraging early treatment, while expanded insurance coverage and government support in developed regions enhance access. This heightened focus supports the market's trajectory through 2031, as more patients seek care.

Leading Players:

Amgen, Inc.
Eli Lilly and Company
Novartis AG
Merck & Co., Inc.
Johnson & Johnson
Pfizer, Inc.
AstraZeneca plc
AbbVie, Inc.
LEO Pharma A/S
Biogen, Inc.

Visit our report to discover essential insights and analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17960

Market Segmentation and Regional Insights

The market segments by treatment type, route of administration, and geography. Biologics lead due to their efficacy in moderate-to-severe cases, followed by topical treatments for milder forms and systemic drugs as a bridge. Injectable biologics dominate administration, with topical creams and oral medications also significant. Distribution occurs via retail pharmacies, hospital pharmacies, and online platforms, with hospitals holding a key share due to biologic administration needs.

Regionally, North America accounted for a significant portion of the US$18.8 billion valuation in 2021, driven by high prevalence, advanced healthcare, and strong biotech presence in the United States. Europe followed, with robust markets in Germany and the UK, supported by universal healthcare systems. The Asia-Pacific region, however, is expected to see the fastest growth through 2031, fueled by rising psoriasis awareness, improving healthcare infrastructure, and biosimilar adoption in China and India.

Challenges and Opportunities

The market faces challenges. High costs of biologics-often exceeding thousands annually-limit accessibility, while side effects like infections or injection-site reactions deter some patients. Generic competition for older drugs pressures pricing, and limited awareness in developing regions delays diagnosis. Regulatory hurdles for new therapies add complexity.

These challenges, however, present opportunities. Companies developing cost-effective biosimilars or oral alternatives could broaden access, supporting the push to US$44 billion. Innovations like small-molecule inhibitors or topical biologics offer growth potential, while telemedicine and patient education in emerging markets could exceed projections. Partnerships with insurers to reduce costs could further enhance reach.

The Road to 2031

By 2031, the global psoriasis treatment market is anticipated to surpass US$44 billion, reflecting ten years of strong growth at an 8.7% CAGR from US$18.8 billion in 2021. This achievement is driven by disease prevalence, therapeutic innovation, and global health efforts. As the forecast concludes, the market's trajectory suggests continued expansion, with potential for personalized treatments to shape future growth.

In conclusion, the psoriasis treatment market demonstrates remarkable growth from 2022 to 2031. Rising from US$18.8 billion to over US$44 billion, it addresses a chronic condition with significant impact. Stakeholders-from pharmaceutical firms to dermatologists-play a vital role in this success, ensuring effective, accessible solutions improve lives worldwide through 2031 and beyond.

Explore Latest Research Reports by Transparency Market Research:

Veterinary Ventilators Market: https://www.pharmiweb.com/press-release/2025-03-18/veterinary-ventilators-market-to-surpass-us-13-bn-by-2035-amid-rising-demand-for-advanced-animal-healthcare-solutions-tmr-research

Wearable Pulse Oximeters Market: https://www.pharmiweb.com/press-release/2025-03-18/wearable-pulse-oximeters-market-to-surpass-us-5945-mn-by-2031-amid-rising-demand-for-smart-health-monitoring-solutions-tmr-research

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com

This release was published on openPR.